José Manuel García Pinilla

Clinical Impact of Drug‐eluting Stents in an Unselected Population of Diabetic Patients

Drug‐eluting stents (DES) have been shown in randomized trials to reduce clinical events in diabetic patients. Our aim was to determine whether these clinical results are applicable in an unselected population of patients with non‐insulin‐dependent diabetes mellitus (NIDDM) and insulin‐dependent diabetes mellitus (IDDM).

Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial: Levosimendan in advanced HF: the LION-HEART trial

The LION‐HEART study was a multicentre, double‐blind, randomised, parallel‐group, placebo‐controlled trial evaluating the efficacy and safety of intravenous administration of intermittent doses of levosimendan in outpatients with advanced chronic heart failure.

Update for 2014 on clinical cardiology, geriatric cardiology, and heart failure and transplantation.

In the present article, we review publications from the previous year in the following 3 areas: clinical cardiology, geriatric cardiology, and heart failure and transplantation. Among the new developments in clinical cardiology are several contributions from Spanish groups on tricuspid and aortic regurgitation, developments in atrial fibrillation, syncope, and the clinical characteristics of heart disease, as well as various studies on familial heart disease and chronic ischemic heart disease. In geriatric cardiology, the most relevant studies published in 2014 involve heart failure, degenerative aortic stenosis, and data on atrial fibrillation in the geriatric population. In heart failure and transplantation, the most noteworthy developments concern the importance of multidisciplinary units and patients with preserved systolic function. Other notable publications were those related to iron deficiency, new drugs, and new devices and biomarkers. Finally, we review studies on acute heart failure and transplantation, such as inotropic drugs and ventricular assist devices.

Clinical Cardiology, Geriatric Cardiology, Heart Failure, and Transplantation 2015: A Selection of Topical Issues.

Manuel Martinez-Selles,* Jose Luis Lambert Rodriguez, Vivencio Barrios, Pablo Diez-Villanueva, Jose Manuel Garcia Pinilla, Juan Cosin, Albert Ariza Sole, Sonia Mirabet Perez, Carlos Escobar, Oscar Diaz-Castro, Javier Segovia Cubero, and Jose Angel Rodriguez a Servicio de Cardiologia, Hospital Universitario Gregorio Maranon, Universidad Europea y Universidad Complutense, Madrid, Spain b Servicio de Cardiologia, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain c Servicio de Cardiologia, Hospital Universitario Ramon y Cajal, Madrid, Spain d Servicio de Cardiologia, Hospital Universitario de la Princesa, Madrid, Spain e Servicio de Cardiologia, Hospital Universitario Virgen de la Victoria, Malaga, Spain f Servicio de Cardiologia, Hospital Arnau de Vilanova, Valencia, Spain g Servicio de Cardiologia, Hospital Universitario de Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain h Servicio de Cardiologia, Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain i Servicio de Cardiologia, Hospital Universitario La Paz, Madrid, Spain j Servicio de Cardiologia, Hospital de Pontevedra, Pontevedra, Spain k Servicio de Cardiologia, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain l Servicio de Cardiologia, Hospital Universitario Juan Canalejo, A Coruna, Spain

Usefulness of Genetic Study by Next-generation Sequencing in High-risk Arrhythmogenic Cardiomyopathy

INTRODUCTION AND OBJECTIVES Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy characterized by progressive fibrofatty replacement of predominantly right ventricular myocardium. This cardiomyopathy is a frequent cause of sudden cardiac death in young people and athletes. The aim of our study was to determine the incidence of pathological or likely pathological desmosomal mutations in patients with high-risk definite ARVC. METHODS This was an observational, retrospective cohort study, which included 36 patients diagnosed with high-risk ARVC in our hospital between January 1998 and January 2015. Genetic analysis was performed using next-generation sequencing. RESULTS Most patients were male (28 patients, 78%) with a mean age at diagnosis of 45 ± 18 years. A pathogenic or probably pathogenic desmosomal mutation was detected in 26 of the 35 index cases (74%): 5 nonsense, 14 frameshift, 1 splice, and 6 missense. Novel mutations were found in 15 patients (71%). The presence or absence of desmosomal mutations causing the disease and the type of mutation were not associated with specific electrocardiographic, clinical, arrhythmic, anatomic, or prognostic characteristics. CONCLUSIONS The incidence of pathological or likely pathological desmosomal mutations in ARVC is very high, with most mutations causing truncation. The presence of desmosomal mutations was not associated with prognosis.

Impact of dynamic physical exercise on high-risk definite arrhythmogenic right ventricular cardiomyopathy: RUIZ SALAS et al.

Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is an inherited cardiomyopathy characterized by ventricular arrhythmias and heart failure. The variable phenotype suggesting that determined environmental factors may have an influence. The aim of our study was to discover the impact of the dynamic physical activity on patients with high‐risk definite ARVC/D.